Clinical TrialMay 27, 2026, 07:02 AM
Atea Pharma's BEM/RZR shows low DDI risk; AT-587 potent for HEV
AI Summary
Atea Pharmaceuticals announced positive Phase 1 results for its fixed-dose combination bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV), demonstrating a low risk of drug-drug interaction with commonly used medications like omeprazole and rosuvastatin. This supports simplified treatment for HCV patients. Additionally, the company presented preclinical data for AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus (HEV), showing high in vitro antiviral potency and in vivo efficacy. Atea plans to advance AT-587 into a first-in-human study mid-year.
Key Highlights
- BEM/RZR Phase 1 results showed low drug-drug interaction risk with omeprazole and rosuvastatin.
- Omeprazole (20mg/40mg) did not meaningfully affect BEM/RZR plasma exposure in healthy adults.
- BEM/RZR exhibited low potential to inhibit P-gp, BCRP, or OATP1B1/3 transporters.
- AT-587 was 30-150x more potent in vitro against HEV than sofosbuvir and ribavirin.
- AT-587 inhibited HEV-3 activity in vivo, significantly reducing HEV RNA levels in gerbil models.
- AT-587 retained high potency against ribavirin and SOF clinical resistance strains in vitro.
- Atea plans to initiate AT-587 first-in-human study by mid-2026.
Price Impact
More from AVIR